Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management

Abstract Background Malignant struma ovarii is an ovarian teratoma containing at least 50% thyroid tissue which has the potential to metastasize and produce thyroid hormone. Given its rarity, management strategies are not well-established. We report a case of metastatic malignant struma ovarii disco...

Full description

Bibliographic Details
Main Authors: Corey J. Lager, Ronald J. Koenig, Richard W. Lieberman, Anca M. Avram
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Clinical Diabetes and Endocrinology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40842-018-0064-5
id doaj-aabb303a7ccb480da8a7c2c61eed5b7f
record_format Article
spelling doaj-aabb303a7ccb480da8a7c2c61eed5b7f2020-11-24T21:30:45ZengBMCClinical Diabetes and Endocrinology2055-82602018-06-01411610.1186/s40842-018-0064-5Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for managementCorey J. Lager0Ronald J. Koenig1Richard W. Lieberman2Anca M. Avram3Division of Metabolism, Endocrinology, and Diabetes, University of MichiganDivision of Metabolism, Endocrinology, and Diabetes, University of MichiganDepartment of Obstetrics and Gynecology and Department of Anatomic Pathology, University of MichiganDepartment of Nuclear Medicine, University of MichiganAbstract Background Malignant struma ovarii is an ovarian teratoma containing at least 50% thyroid tissue which has the potential to metastasize and produce thyroid hormone. Given its rarity, management strategies are not well-established. We report a case of metastatic malignant struma ovarii discovered during pregnancy with lessons for evaluation and management. Case presentation A 30-year-old woman who was two months pregnant was discovered to have struma ovarii with over half of the struma comprised of papillary thyroid cancer. Following tumor resection, delivery, and thyroidectomy, she underwent evaluation with stimulated thyroglobulin testing and diagnostic staging sodium iodide-131 scan (I-131), which revealed the presence of skeletal metastases. Following administration of 320 mCi I-131, post-therapy scan also showed miliary pulmonary metastases with improved ability to localize the bony and pulmonary metastases with concurrent SPECT/CT imaging. A second dosimetry-guided I-131 therapy resulted in complete resolution of pulmonary metastases; however, small foci of residual bone disease persisted. Post-therapy scans demonstrated additional findings not shown on diagnostic I-131 scans obtained prior to both her initial and second I-131 therapy. Conclusions SPECT/CT provides accurate anatomic correlation and localization of metastatic foci and can serve as a baseline study to assess interval response to treatment. Post-therapy scans should always be obtained when I-131 treatment is administered, as additional findings may be revealed versus low dose I-131 activity diagnostic scans. This patient had a high metastatic burden that would not have been discovered in a timely fashion with the conservative approach advocated by others. Thyroidectomy followed by a diagnostic staging radioiodine scan and a stimulated thyroglobulin level should be considered in patients with malignant struma ovarii for guiding therapeutic I-131 administration as metastatic risk is difficult to predict based on histopathologic examination.http://link.springer.com/article/10.1186/s40842-018-0064-5Struma ovariiThyroid cancerRadioactive iodineThyroid imagingPregnancy
collection DOAJ
language English
format Article
sources DOAJ
author Corey J. Lager
Ronald J. Koenig
Richard W. Lieberman
Anca M. Avram
spellingShingle Corey J. Lager
Ronald J. Koenig
Richard W. Lieberman
Anca M. Avram
Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management
Clinical Diabetes and Endocrinology
Struma ovarii
Thyroid cancer
Radioactive iodine
Thyroid imaging
Pregnancy
author_facet Corey J. Lager
Ronald J. Koenig
Richard W. Lieberman
Anca M. Avram
author_sort Corey J. Lager
title Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management
title_short Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management
title_full Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management
title_fullStr Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management
title_full_unstemmed Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy – Lessons for management
title_sort rare clinical entity: metastatic malignant struma ovarii diagnosed during pregnancy – lessons for management
publisher BMC
series Clinical Diabetes and Endocrinology
issn 2055-8260
publishDate 2018-06-01
description Abstract Background Malignant struma ovarii is an ovarian teratoma containing at least 50% thyroid tissue which has the potential to metastasize and produce thyroid hormone. Given its rarity, management strategies are not well-established. We report a case of metastatic malignant struma ovarii discovered during pregnancy with lessons for evaluation and management. Case presentation A 30-year-old woman who was two months pregnant was discovered to have struma ovarii with over half of the struma comprised of papillary thyroid cancer. Following tumor resection, delivery, and thyroidectomy, she underwent evaluation with stimulated thyroglobulin testing and diagnostic staging sodium iodide-131 scan (I-131), which revealed the presence of skeletal metastases. Following administration of 320 mCi I-131, post-therapy scan also showed miliary pulmonary metastases with improved ability to localize the bony and pulmonary metastases with concurrent SPECT/CT imaging. A second dosimetry-guided I-131 therapy resulted in complete resolution of pulmonary metastases; however, small foci of residual bone disease persisted. Post-therapy scans demonstrated additional findings not shown on diagnostic I-131 scans obtained prior to both her initial and second I-131 therapy. Conclusions SPECT/CT provides accurate anatomic correlation and localization of metastatic foci and can serve as a baseline study to assess interval response to treatment. Post-therapy scans should always be obtained when I-131 treatment is administered, as additional findings may be revealed versus low dose I-131 activity diagnostic scans. This patient had a high metastatic burden that would not have been discovered in a timely fashion with the conservative approach advocated by others. Thyroidectomy followed by a diagnostic staging radioiodine scan and a stimulated thyroglobulin level should be considered in patients with malignant struma ovarii for guiding therapeutic I-131 administration as metastatic risk is difficult to predict based on histopathologic examination.
topic Struma ovarii
Thyroid cancer
Radioactive iodine
Thyroid imaging
Pregnancy
url http://link.springer.com/article/10.1186/s40842-018-0064-5
work_keys_str_mv AT coreyjlager rareclinicalentitymetastaticmalignantstrumaovariidiagnosedduringpregnancylessonsformanagement
AT ronaldjkoenig rareclinicalentitymetastaticmalignantstrumaovariidiagnosedduringpregnancylessonsformanagement
AT richardwlieberman rareclinicalentitymetastaticmalignantstrumaovariidiagnosedduringpregnancylessonsformanagement
AT ancamavram rareclinicalentitymetastaticmalignantstrumaovariidiagnosedduringpregnancylessonsformanagement
_version_ 1725961908824047616